Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Autoimmune hepatitis (AIH) is characterized by chronic inflammation of the liver, interface hepatitis, hypergammaglobulinemia, and the presence of autoantibodies. Disease presentation is varied but typically is based on characteristic aminotransferase elevations, histological abnormalities, elevated levels of serum globulins, and the presence of one or more autoantibodies. Two types of juvenile AIH have been identified according to seropositivity for smooth muscle and /or antinuclear antibody (AIH type 1) or liver kidney microsomal antibody (AIH type 2). Standard therapy in clinic consists of a combination of corticosteroids and azathioprine, which displays the efficacy in 80% of patients. However, 7% of patients deteriorate despite compliance with the standard corticosteroid regiments (treatment failure),13% of patients improve but not to a degree that satisfies remission criteria (incomplete response), 13% of patients develop serious drug-induced complications, and 50%-86% of patients will relapse after drug withdrawal. These serious drawbacks counterbalance the benefits of conventional therapy, and they are compelling reasons to refine current treatment strategies and pursue alternative therapies. UC-MSC has been the application for the treatment of several severe autoimmune diseases, such as immune thrombocytopenia, systemic lupus erythematosus, and therapy-resistant rheumatoid arthritis. In this study, the safety and efficacy of UC-MSC transplantation for AIH patients will be evaluated.
| Condition | Intervention | Phase |
|---|---|---|
|
Autoimmune Hepatitis |
Other: conventional plus UC-MSC treatment Other: Conventional plus placebo treatment |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Autoimmune Liver Disease |
- Liver Histology change [ Time Frame: baseline and 96 weeks ] [ Designated as safety issue: No ]
- Serum alanine aminotransferase (ALT) [ Time Frame: 0,12, 24, 36, 48, 72, 96 weeks after treatment ] [ Designated as safety issue: No ]
- Serum AST [ Time Frame: At baseline and at week 12, 24, 36, 48, 72, 96 ] [ Designated as safety issue: No ]
- Serum Tbil [ Time Frame: At baseline and at week 12, 24, 36, 48, 72, 96 ] [ Designated as safety issue: No ]
- Serum immunoglobulin G (IgG) [ Time Frame: At baseline and at week 12, 24, 36, 48, 72, 96 ] [ Designated as safety issue: No ]
- Serum γ-globulin [ Time Frame: At baseline and at week 12, 24, 36, 48, 72, 96 ] [ Designated as safety issue: No ]
- MELD score [ Time Frame: At base line and at week 12, 24, 36, 48, 72, 96 ] [ Designated as safety issue: No ]
- Number of participants with treatment side effects [ Time Frame: At base line and at week 12, 24, 36, 48, 72, 96 ] [ Designated as safety issue: No ]weight gain, acne, facial rounding, dorsal hump formation, hirsutism, osteopenia and diabetes mellitus, et al
- Number of participants with improvement of clinical symptoms [ Time Frame: At base line and at week 12, 24, 36, 48, 72, 96 ] [ Designated as safety issue: No ]diffuse arthralgias, fatigue, generalized malaise, jaundice, abdominal pain, nausea, and loss of appetite
| Estimated Enrollment: | 100 |
| Study Start Date: | October 2011 |
| Estimated Study Completion Date: | October 2014 |
| Estimated Primary Completion Date: | October 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Conventional plus UC-MSC treatment
Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit. |
Other: conventional plus UC-MSC treatment
Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
|
|
Experimental: Conventional plus placebo treatment
Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit.
|
Other: Conventional plus placebo treatment
Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
|
Detailed Description:
Autoimmune hepatitis (AIH) is an immune-mediated necroinflammatory disease of the liver characterized by elevation of IgG, presence of characteristic autoantibodies, and histological feature of interface hepatitis. Standard therapy consists of a combination of corticosteroids and azathioprine, which is efficacious in 80% of patients. However, current treatment strategies are complicated by frequent relapse after drug withdrawal, medication intolerance, and refractory disease. Alternative medical therapy may be need for AIH.
The potential for stem cells to differentiate into hepatocytes cells was recently confirmed. In particular, bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has been applicated in the clinic for treat several human disease such as GVHD, cardiac injury and brain injury, and displayed good tolerance and efficiency. Recently, umbilical cord-derived MSCs (UC-MSC) has also been used to treat severe autoimmune diseases, such as immune thrombocytopenia, systemic lupus erythematosus, and therapy-resistant rheumatoid arthritis.
The purpose of this study is to learn whether and how UC-MSC can improve the disease condition in patients with autoimmune hepatitis (AIH). This study will also look at how well UC-MSC is tolerated and its safety in AIH patients
Participants in the study will be randomly assigned to one of two treatment arms:
Arm A: Participants will receive 12 weeks of UC-MSC treatment plus conventional treatment (combination of corticosteroids and azathioprine) Arm B: Participants will receive 12 weeks of placebo plus conventional treatment. (combination of corticosteroids and azathioprine) UC-MSC will be prepared according to standard procedures and is collected in plastic bags containing anticoagulant. UC-MSCs are given via i.v. under sonography monitoring. After cell therapy, patients are followed up at week 12, 24, 36, 48, 72, 96. The evaluation of some clinical parameters such as the level of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-globulin, total bilirubin (TB), prothrombin time (PT), albumin (ALB), prealbumin (PA) and IgG, are detected at these time points. MELD score, Liver histology, treatment side effects, relapse rate and clinical symptoms were also observed simultaneously.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent
- Autoimmune hepatitis (according to the criteria defined by the international autoimmune hepatitis Group ,Hepatology, 2008;48:169-176)
- Negative pregnancy test (female patients in fertile age)
Exclusion Criteria:
- Hepatocellular carcinoma or other Malignancies
- Pregnant or lactating women
- Viral Hepatitis ( HAV,HBV,HCV, et al )
- Vital organs failure (Cardiac, Renal or Respiratory, et al)
- Sepsis
- Active thrombosis in the portal or hepatic veins
Contacts and Locations| Contact: Fu-Sheng Wang, professor | 86-10-63879735 ext 2015.12 | fswang302@163.com |
| Contact: Zheng Zhang, Doctor | 86-10-63879735 ext 2015.12 | Zhangzheng1975@yahoo.com.cn |
| China, Beijing | |
| Beijing 302 Hospital | Recruiting |
| Beijing, Beijing, China, 100039 | |
| Contact: Fu-Sheng Wang, professor 86-10-63879735 ext 2015.12 fswang302@163.com | |
| Contact: Lifeng Wang, Doctor 86-10-63879735 ext 2015.12 wanglf76@gmail.com | |
| Principal Investigator: Fu-Sheng Wang, Professor | |
| Principal Investigator: | Fu-Sheng Wang, professor | Beijing 302 Hospital |
More Information
Publications:
| Responsible Party: | Fu-sheng Wang, Director of both the Research Center for Biological Therapy and the Beijing Institute of Translational Hepatology, Beijing 302 Hospital |
| ClinicalTrials.gov Identifier: | NCT01661842 History of Changes |
| Other Study ID Numbers: | Beijing302-006 |
| Study First Received: | August 5, 2012 |
| Last Updated: | August 9, 2012 |
| Health Authority: | China: Ministry of Health |
Keywords provided by Beijing 302 Hospital:
|
Autoimmune Hepatitis Mesenchymal stem cells serum albumin serum Tbil serum immunoglobulin G(IgG) |
Additional relevant MeSH terms:
|
Hepatitis, Autoimmune Autoimmune Diseases Hepatitis Hepatitis A Liver Diseases Digestive System Diseases Hepatitis, Viral, Human |
Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Hepatitis, Chronic Immune System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013